Abstracts tagged "osteoporosis"

Abstract Number: 2004 • ACR Convergence 2023
Bone Health Following Bariatric Surgery: A Single Center Quality Improvement Study
Andrew Benck, Haley Zimmerman, Amy Trang, Najia Shakoor and Sonali Khandelwal, Rush University, Chicago, IL
Background/Purpose: Osteoporosis related fractures cause significant morbidity and mortality. Bariatric weight loss surgery is an independent risk factor for osteoporosis. Post-surgery dual energy X-Ray absorptiometry…
Abstract Number: 2138 • ACR Convergence 2023
Frailty Is a Predictor of Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis
K Wysham¹, Hannah Brubeck², Aaron Baraff³, Punyasha Roul⁴, Namrata Singh⁵, James Andrews⁶, Grant Cannon⁷, Gary Kunkel⁸, Ted R Mikuls⁹, Bryant England⁴, Dolores Shoback¹⁰, Patti Katz¹¹, Jose Garcia¹², Ariela Orkaby¹³ and Joshua Baker¹⁴, ¹VA Puget Sound/University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³VA Puget Sound Seattle, Seattle, WA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Washington, Bellevue, WA, ⁶University of Washington, Seattle, WA, ⁷University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁸University of Utah, Salt Lake City, UT, ⁹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ¹⁰San Francisco VA Medical Center, San Francisco, CA, ¹¹University of California San Francisco, San Rafael, CA, ¹²VA Puget Sound Healthcare System, Seattle, WA, ¹³Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Frailty occurs prematurely in RA. Levels of frailty are higher in Veteran populations than civilians1. Frailty has been shown to predict osteoporotic fractures in…
Abstract Number: 2005 • ACR Convergence 2023
Secondary Prevention of Osteoporosis in Hip Fracture Care for Elderly Patients. Clinical and Functional Profile of Users
Belén Miguel Ibáñez, Alfonso González Ramírez, Olga Martínez González, Ana Isabel Turrión Nieves, Marta Ibáñez Martínez, Carolina Cristina Chacón Vélez, Laura Blanco Ramis, Manuel Cipriano Martín Martínez, Cristina Hidalgo Calleja, Carlos Alberto Montilla Morales, Susana Gómez Castro, Juan Francisco Blanco Blanco and Carmen Pablos Hernández, University Healthcare Complex of Salamanca, Salamanca, Spain
Background/Purpose: Osteoporosis is a first-rate problem in an increasingly ageing population. Falls among the elderly are a severe geriatric syndrome with relevant secondary effects. Fractures…
Abstract Number: 2429 • ACR Convergence 2023
Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial
Chi Chiu Mok¹, SAU MEI TSE², Kar Li Kelly Chan³ and Wai Han Ma¹, ¹Tuen Mun Hospital, Hong Kong, Hong Kong, ²Tuen Mun Hospital, Hong Kong, China, ³Tuen Mun Hospital, Shatin, China
Background/Purpose: To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients treated with glucocorticoids (GCs). Methods: Adult patients (≥18 years)…
Abstract Number: 2006 • ACR Convergence 2023
Improvement of Care: Osteoporosis Screening in a Resident-led Primary Care Clinic
Massiel Jimenez Artiles¹, Roshan Subedi², Qi Wang³, Bishara Jahshan⁴, Khalid Gadir⁴ and Waleed Quwatli⁵, ¹Unity Hospital, Rochester Regional Health, Greece, NY, ²Rochester Regional Health/Unity Hospital, Greece, NY, ³Rochester Regional Health/Unity Hospital, Rochester, NY, ⁴Unity Hospital, Rochester Regional Health, Rochester, NY, ⁵Unity Hospital/ Rochester Regional Health, Rochester, NM
Background/Purpose: Osteoporotic fractures, especially hip fractures, are associated with significant morbidity, including limitations in ambulation, disability, and decreased quality of life. The aim of this…
Abstract Number: 2527 • ACR Convergence 2023
Risk Factors for Bone Loss in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: Osteoporotic fractures are the most common damage item from the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index. Previous…
Abstract Number: 1072 • ACR Convergence 2023
Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors
Maria Suarez-Almazor¹, Carrie Ye², Bo Zhao³, Juan Ruiz³, Hui Zhao³, Noha Abdel-Wahab⁴ and William Leslie⁵, ¹MD Anderson Cancer Center, Houston, TX, ²University of Alberta, Edmonton, AB, Canada, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, Houston, TX, ⁵University of Manitoba, Internal Medicine, Winnipeg, MB, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. Despite their efficacy on tumor outcomes they can cause severe and sometimes long-standing immune-related…
Abstract Number: 2007 • ACR Convergence 2023
Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study
Insa Mannstadt, Donald McMahon, Douglas Mintz, Weija Yuan, Linda Russell, Susan Goodman, Emily Stein and Dalit Ashany, Hospital for Special Surgery, New York, NY
Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…
Abstract Number: 2528 • ACR Convergence 2023
Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
Min Kim¹, Vanessa C. Brunetti¹, Felicia Cosman², Jeffrey Curtis³, E Michael Lewiecki⁴, Matthew Phelan⁵, Peter Samai⁵, Michele McDermott¹, Tzu-Chieh Lin¹, M Alan Brookhart⁶ and Kathleen Hurwitz⁵, ¹Amgen, Inc., Thousand Oaks, CA, ²Columbia University, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵Target RWE, Durham, NC, ⁶Department of Population Health Sciences, Duke University, Durham, NC
Background/Purpose: Recent studies suggest that post-fracture pharmacologic management has been declining in the U.S. despite an increase in the burden of osteoporosis (OP). In light…
Abstract Number: 1098 • ACR Convergence 2023
Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Kelly Tran¹, Ellen Ann Sockman¹, Rachel Salyer¹, Megan Young¹, Aisha Abbasi¹ and Devanshu Verma², ¹West Virginia University Hospital, Morgantown, WV, ²West Virginia University, Morgantown, WV
Background/Purpose: Osteoporosis is a medical condition associated with decreased bone mass and bone architecture, which increases incidence of fragility fractures(4). It is associated with 1.5…
Abstract Number: 2008 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Jeffrey Curtis¹, Tarun Arora², Ye Liu¹, Tzu-Chieh Lin³, Leslie Spangler³, Vanessa C. Brunetti³, Robert K. Stad³, Michele McDermott³, Brian D. Bradbury³ and Min Kim³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking…
Abstract Number: 2529 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Jeffrey R Curtis¹, Tarun Arora², Ye Liu³, Vanessa C. Brunetti⁴, Tzu-Chieh Lin⁴, Leslie Spangler⁴, Robert K. Stad⁴, Michele McDermott⁴, Brian D. Bradbury⁴ and Min Kim⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…
Abstract Number: 1620 • ACR Convergence 2023
Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab
Ye Liu¹, Tarun Arora², S. Bobo Tanner³ and Jeffrey Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Romosozumab (romo) and denosumab (dmab) are recommended for postmenopausal women with osteoporosis (OP) at high risk of fracture. The U.S. prescribing information includes a…
Abstract Number: 2009 • ACR Convergence 2023
Screening and Treatment of Low Bone Mineral Density in Allogeneic Hematopoietic Cell Transplant Patients
Perry Fuchs, Christina Ferraro, Chao Zhang, Chad Deal, Betty Hamilton and Sarah Keller, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Bone mineral density (BMD) loss and fracture are important causes of increased morbidity following allogeneic hematopoietic stem cell transplant (allo-HCT).Recent societal recommendations support screeningDual…
Abstract Number: 2530 • ACR Convergence 2023
Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center
Sarah Keller¹, Adil Vural², Jennifer Varley², Komal Mushtaq², Walaa Abu Alya³, Neel Tapryal², Hassan Shaheen³, Marie Budev², Abby Abelson² and Chad Deal¹, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic Fairview Hospital, Cleveland, OH
Background/Purpose: Osteoporotic fractures are a well-known complication in LT recipients, significantly impacting their quality of life. Specific risk factors for these fractures in LT recipients…

« Previous Page
1
…
7
8
9
10
11
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].